Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V 1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The limbic localization of the arginine vasopressin V 1b receptor has prompted speculation as to a potential role of this receptor in the control of emotional processes. To investigate this possibility, we have studied the behavioral effects of SSR149415, the first selective and orally active non-peptide antagonist of vasopressin V 1b receptors, in a variety of classical (punished drinking, elevated plus-maze, and light/dark tests) and atypical (fear/anxiety defense test battery and social defeat-induced anxiety) rodent models of anxiety, and in two models of depression [forced swimming and chronic mild stress (CMS)]. When tested in classical tests of anxiety, SSR149415 produced anxiolytic-like activity at doses that ranged from 1 to 30 mg/kg (i.p. or p.o.), but the magnitude of these effects was overall less than that of the benzodiazepine anxiolytic diazepam, which was used as a positive control. In contrast, SSR149415 produced clear-cut anxiolytic-like activity in models involving traumatic stress exposure, such as the social defeat paradigm and the defense test battery (1–30 mg/kg, p.o.). In the forced swimming test, SSR149415 (10–30 mg/kg, p.o.) produced antidepressant-like effects in both normal and hypophysectomized rats. Moreover, in the CMS model in mice, repeated administration of SSR149415 (10 and 30 mg/kg, i.p.) for 39 days improved the degradation of the physical state, anxiety, despair, and the loss of coping behavior produced by stress. These findings point to a role for vasopressin in the modulation of emotional processes via the V 1b receptor, and suggest that its blockade may represent a novel avenue for the treatment of affective disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
Pellow, S., Chopin, P., File, S. E., & Briley, M. (1985) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(85)90031-7 · Cited by 5,822
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
Neurocircuitry of stress: central control of the hypothalamo–pituitary–adrenocortical axis
Herman, J. P., & Cullinan, W. E. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10069-2 · Cited by 2,270
Chronic mild stress-induced anhedonia: A realistic animal model of depression
Willner, P., Muscat, R., & Papp, M. (1992) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80194-0 · Cited by 1,160
A simple and reliable conflict procedure for testing anti-anxiety agents
Vogel, J. R., Beer, B., & Clody, D. E. (1971) · Psychopharmacologia · doi:10.1007/bf00403989 · Cited by 841
Ethopharmacological analysis of rat behavior on the elevated plus-maze
Cruz, A. P. M., Frei, F., & Graeff, F. G. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90472-3 · Cited by 823
de Vries, G. J., & Buijs, R. M. (1983) · Brain Research · doi:10.1016/0006-8993(83)90855-7 · Cited by 565
Molecular cloning and expression of a rat Via arginine vasopressin receptor
Morel, A., O'Carroll, A.-M., Brownstein, M. J., & Lolaft, S. J. (1992) · Nature · doi:10.1038/356523a0 · Cited by 477
Animal models for the study of anti-anxiety agents: A review
Treit, D. (1985) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(85)90046-6 · Cited by 450
Miczek, K. A. (1979) · Psychopharmacology · doi:10.1007/bf00426664 · Cited by 397
Research works printed but not linked: 3
- D De Wied J Endocrinol 48, xlv–xlvi (1970).
- R Dantzer, R M Bluthe Crit Rev Neurobiol 6, 243–255 (1992).
- J Simiand, P E Keane, M C Barnouin, M Keane, P Soubrié, G Le Fur Fundam Clin Pharmacol 7, 413–427 (1993).
Cited by
Items 301–400 of 524
Finger release sequence for fastball and curveball pitches.
Stevenson, J. M. (1985) · PubMed · Cited by 22
Zhang, L., Xu, M., Cao, W., Xu, X., & Ji, S. (2020) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202000637 · Cited by 21
Vasopressinergic control of stress-related behavior: studies in Brattleboro rats
Csikota, P., Fodor, A., Balázsfi, D., Pintér, O., Mizukami, H., Weger, S., Heilbronn, R., Engelmann, M., & Zelena, D. (2016) · Stress · doi:10.1080/10253890.2016.1183117 · Cited by 21
“Indeed, a V1b receptor antagonist, SSR149415 produced anxiolytic- and antidepressant-like effects in numerous preclinical tests (Griebel et al., 2002) in both rats and mice (Rotzinger et al., 2010).”
BackgroundResultInfluentialProspects for the Treatment of Depression
Norman, T. R. (2006) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2006.01814.x · Cited by 21
“Activity in the forced swim test was present in hypophysectomized animals, suggesting that the antidepressantlike effect is independent of the influence over the HPA axis [73].”
BackgroundOxytocin, Vasopressin and Stress: A Hormetic Perspective
Nazarloo, H. P., Kingsbury, M. A., Lamont, H., Dale, C. V., Nazarloo, P., Davis, J. M., Porges, E. C., Cuffe, S. P., & Carter, C. S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47080632 · Cited by 20
“The functions of both are shaped by epigenetics [101,144] and modulate neuroimmune and autonomic functions [6,81,113].”
Class A and C GPCR Dimers in Neurodegenerative Diseases
Moreira, I. S., Caniceiro, A. B., Bueschbell, B., & Schiedel, A. C. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220327221830 · Cited by 20
Agorastos, A., Sommer, A., Heinig, A., Wiedemann, K., & Demiralay, C. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00453 · Cited by 20
Antagonistas del receptor de vasopresina: los vaptanes
Villabona, C. M. (2010) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(10)70021-8 · Cited by 20
Effects of Cocaine on Maternal Behavior and Neurochemistry
Nephew, B. C., & Febo, M. (2012) · Current Neuropharmacology · doi:10.2174/157015912799362760 · Cited by 20
Karahan, S., & Tanyeli, C. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob02208b · Cited by 20
A complex selection signature at the human AVPR1B gene
Cagliani, R., Fumagalli, M., Pozzoli, U., Riva, S., Cereda, M., Comi, G. P., Pattini, L., Bresolin, N., & Sironi, M. (2009) · BMC Evolutionary Biology · doi:10.1186/1471-2148-9-123 · Cited by 20
Chapter 10 rTMS as treatment strategy in psychiatric disorders – neurobiological concepts
Keck, M. E. (2003) · Supplements to Clinical neurophysiology · doi:10.1016/s1567-424x(09)70213-2 · Cited by 20
HAB/LAB rats: an animal model of extremes in trait anxiety and depression
Landgraf, R. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00085-9 · Cited by 20
Zhou, Y., & Kreek, M. J. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.245621 · Cited by 19
“vasopressin (AVP) neuronal activity is involved in important steps in several rodent models (Griebel et al., 2002; Salome et al., 2006; Roper et al., 2011) and in humans (Katz et al.”
BackgroundKingston, R., Amin, D., Misra, S., Gross, J. M., & Kuwajima, T. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009885 · Cited by 19
“The dose (10mg/kg, IP, daily) of fluoxetine was utilized in this study since it has been reported to show robust effects on stress-related behavior [74], several motor behaviors [75] and retinal axon formation from RGCs to the superior colliculus [28,76].”
MethodHernández‐Pérez, O. R., Crespo‐Ramírez, M., Ferrer, Y. C., Anías-Calderón, J., Zhang, L., Roldán-Roldán, G., Aguilar‐Roblero, R. A., Borroto‐Escuela, D. O., Fuxé, K., & de la Mora, M. P. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4817-0 · Cited by 19
Reymond‐Marron, I., Tribollet, E., & Raggenbass, M. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05038.x · Cited by 19
“The V1b receptor antagonist SSR149415 appears to exert anxiolytic- and antidepressantlike effects (Griebel et al., 2002; Stemmelin et al., 2005).”
BackgroundTherapeutics for depression and anxiety disorders
Holsboer, F. (2004) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2004.08.012 · Cited by 19
Nguyen, E. T., Selmanovic, D., Maltry, M., Morano, R. L., Franco, A. C. G., Estrada, C. M., & Solomon, M. B. (2020) · Hormones and Behavior · doi:10.1016/j.yhbeh.2020.104852 · Cited by 18
Saavedra, J. M., & Pavel, J. (2005) · Drug Development Research · doi:10.1002/ddr.20027 · Cited by 18
Santarelli, L., & Saxe, M. (2003) · CNS Spectrums · doi:10.1017/s1092852900018861 · Cited by 18
Yang, J., Pan, Y.-J., Yin, Z., Hai, G.-F., Lu, L., Zhao, Y. Y., Wang, D., Wang, H., & Wang, G. (2012) · Neuropeptides · doi:10.1016/j.npep.2012.03.003 · Cited by 17
Yue, J., Ma, X., Liu, X., Wang, J., Liu, X., & Zhou, Y. (2020) · Green Chemistry · doi:10.1039/d0gc00130a · Cited by 17
Emerging treatments for major depression
Norman, T. R., & Burrows, G. D. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.2.203 · Cited by 17
Cellular dehydration acutely degrades mood mainly in women: a counterbalanced, crossover trial
Suh, H., Lieberman, H. R., Jansen, L. T., Colburn, A. T., Adams, J. D., Seal, A., Butts, C. L., Kirkland, T. W., Melander, O., Vanhaecke, T., et al. (2020) · British Journal Of Nutrition · doi:10.1017/s0007114520003475 · Cited by 16
“Another animal study orally administered a V1bR antagonist to mice and observed antidepressantlike effects(45).”
BackgroundVasopressin and post-traumatic stress disorder
Sipos, E., Török, B., Barna, I., Engelmann, M., & Zelena, D. (2020) · Stress · doi:10.1080/10253890.2020.1826430 · Cited by 16
Qi, X., Guzhva, L., Ji, Y. R., & Bruijnzeel, A. W. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.06.031 · Cited by 16
Milutinović‐Smiljanić, S., Šarenac, O., Lozić, M., Murphy, D., & Japundžić‐Žigon, N. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12161 · Cited by 16
“V1b receptors found in BNST have been found to contribute crucially to the emotional response to stress (Griebel et al., 2002), and strong emotions can increase BP and HR. BNST is abundantly interconnected with the hypothalamus, Table 2 Effects of stress on SBP, MBP, DBP, HR and BRS in rats…”
BackgroundInfluentialCsabafi, K., Ibos, K. E., Bodnár, É., Filkor, K., Szakács, J., & Bagosi, Z. (2023) · Biomedicines · doi:10.3390/biomedicines11092446 · Cited by 15
“V1bRs have been implicated in anxiety since treatment with a selective nonpeptide V1b antagonist (SSR149415) has exerted an anxiolytic-like and antidepressive-like effect in a battery of behavioral tests in mice [56].”
ANXIOLYTICS: Origins, drug discovery, and mechanisms
Witkin, J. M., & Barrett, J. E. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173858 · Cited by 15
Tong, Y., Pfeiffer, L., Serchov, T., Coenen, V. A., & Döbrössy, M. D. (2022) · Journal of Neuroscience Research · doi:10.1002/jnr.25014 · Cited by 15
“CMUS has shown both decreasing (D’Aquila et al., 1994; Kopp et al., 1999) and increasing (Griebel et al., 2002; Monteiro et al., 2015) anxiety-like behavior as measured on the EPM.”
MethodAGONIST OF V2 VASOPRESSIN RECEPTOR REDUCES DEPRESSIVE DISORDERS IN POST-STROKE PATIENTS
Belokoskova, S. G., Stepanov, I. I., & Tsikunov, S. G. (2012) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn.v67i4.197 · Cited by 15
Yu, Y.-N., Qi, W., Wu, C., & Xu, M. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b02787 · Cited by 15
Rajkumar, R., & Mahesh, R. (2008) · Current Neuropharmacology · doi:10.2174/157015908785777256 · Cited by 15
“SR149415, the selective (and orally active) AVP-1B receptor antagonist exhibited antidepressant-like effects in FST [102] and olfactory bulbectomy [137] models in rats.”
BackgroundZhu, L., Chu, X., Ren, J., Chang, L., Zhu, X., Sun, N., Meng, G., Liu, M., Zhang, J., Li, Y., et al. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13269 · Cited by 15
Goutier, W., Kloeze, M. B., & McCreary, A. C. (2014) · Addiction Biology · doi:10.1111/adb.12190 · Cited by 14
“Previous reports have described the pharmacological actions of vasopressin V1b receptor antagonists for the treatment of a variety of psychiatric conditions including stroke, depression and anxiety (Griebel et al. 2002).”
BackgroundPrévot, T. D., Viollet, C., Epelbaum, J., Dominguez, G., Béracochéa, D., & Guillou, J. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.01.022 · Cited by 14
“Deterioration of the fur due to either metabolic changes or a depression-induced reduction of grooming behavior is considered as an indicator for a depression-like emotional state (Griebel et al., 2002; Santarelli et al., 2003).”
BackgroundMuthusamy, S., Balasubramani, A., & Suresh, E. (2018) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201801106 · Cited by 14
Behavioral Roles of Oxytocin and Vasopressin
Benjamin, C. (2012) · InTech eBooks · doi:10.5772/50422 · Cited by 14
Yoshitake, S., Ijiri, S., Kehr, J., & Yoshitake, T. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.12.011 · Cited by 14
Control of Stress-Induced ACTH Secretion by Vasopressin and CRH: Additional Evidence
Ramos, A. T., Tufik, S., & Troncone, L. R. P. (2016) · Neuropsychobiology · doi:10.1159/000445480 · Cited by 14
The future of antidepressant pharmacotherapy.
Baldwin, D. S., & Thompson, C. (2003) · Europe PMC (PubMed Central) · Cited by 14
Iron(III) Chloride as a Mild Catalyst for the Dearomatizing Cyclization of N-Acylindoles
Zhang, J., Li, J., Ward, J. S., Truong, K., Rissanen, K. T., & Albrecht, M. (2020) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.0c01373 · Cited by 13
Shariatifar, A., Riazi, M., Ebnolelm, M., & Jahromy, M. H. (2014) · Chinese Medicine · doi:10.4236/cm.2014.51003 · Cited by 13
Xue, Y., Wang, Y., Cao, Z., Zhou, J. E., & Chen, Z. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob01611a · Cited by 13
The Role of Vasopressin in Anxiety and Depression
Morales‐Medina, J. C., Witchey, S. K., & Caldwell, H. K. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_40 · Cited by 13
Luo, W., Luo, Y., & Yang, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-66420-z · Cited by 14
Claustre, Y., Rouquier, L., Desvignes, C., Leonetti, M., Montégut, J., Aubin, N., Allouard, N., Bougault, I., Oury-Donat, F., & Steinberg, R. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.05.006 · Cited by 13
Comparative pharmacology of bovine, human and rat vasopressin receptor isoforms
Andrés, M., Peña, A., Derick, S., Raufaste, D., Trojnar, J., Wiśniewski, K., Trueba, M., Gal, C. S., & Guillon, G. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.08.026 · Cited by 13
Fu, P., Liu, C.-P., Liu, C.-Y., Zhang, Y.-C.-F., Xu, J.-P., Mao, R.-T., Ding, X., Li, F., Zhang, Y.-L., Yang, H., et al. (2025) · Research · doi:10.34133/research.0701 · Cited by 12
“While these studies collectively support our current findings, our study is the first to demonstrate the pivotal role of AVP in the HW model, potentially mediated through AVPR1b, which has been previously implicated in depressive-like behaviors [ 83 – 85 ].”
Grigorenko, E. L. (2011) · Wiley eBooks · doi:10.1002/9781118092699.ch3 · Cited by 12
Vares, M., Metelitsa, M., Kõiv, K., Kaldmäe, M., Laugus, K., Tiitsaar, K., Shimmo, R., & Harro, J. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.05.014 · Cited by 12
Modeling Human Anxiety and Depression in Mutant Mice
Holmes, A., & Cryan, J. F. (2006) · Contemporary clinical neuroscience · doi:10.1007/978-1-59745-058-4_12 · Cited by 12
New directions in the treatment of anxiety disorders
Hood, S. D., Argyropoulos, S. V., & Nutt, D. (2003) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.13.4.401 · Cited by 12
Collins, D., Randesi, M., da Rosa, J. C., Zhang, Y., & Kreek, M. J. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4965-x · Cited by 11
Vasopressin receptor antagonists: a patent summary (2018-2022)
Baska, F., Bozó, É., & Patócs, T. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2218546 · Cited by 11
Baldwin, D. S., & Garner, M. J. (2008) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(07)00018-5 · Cited by 11
Guillon, G., Peña, A., Murat, B., Derick, S., Trueba, M., Ventura, M. A., Szeto, H. H., Wo, N. C., Stoev, S. B., Cheng, L., et al. (2005) · Journal of Peptide Science · doi:10.1002/psc.710 · Cited by 11
Evidence for the contribution of vasopressin V1B receptors in the pathophysiology of depression
Guan, W., Wang, Q., & Sheng, X.-M. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116672 · Cited by 10
Drug-induced suppression of ACTH secretion does not promote anti-depressive or anxiolytic effects
Ramos, A. T., Homem, K. S. D. C., Suchecki, D., Tufik, S., & Troncone, L. R. P. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.02.024 · Cited by 10
Higuchi, Y., & Arakawa, H. (2022) · Hormones and Behavior · doi:10.1016/j.yhbeh.2022.105128 · Cited by 10
Adongo, D. W., Mante, P. K., Kukuia, K. K. E., Benneh, C. K., Biney, R. P., Boakye‐Gyasi, E., Amekyeh, H., Harley, B. K., Tandoh, A., Okyere, P. D., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0278231 · Cited by 10
Miklos, Z., Flynn, F. W., & Lessard, A. (2014) · Brain Research · doi:10.1016/j.brainres.2014.09.043 · Cited by 10
Approche neurobiologique de la dépression : nouvelles données
Lanfumey, L., & Hamon, M. (2005) · Therapies · doi:10.2515/therapie:2005064 · Cited by 10
Holsboer, F., & Ising, M. (2024) · Pharmacopsychiatry · doi:10.1055/a-2372-3549 · Cited by 9
Penta, P. T., Villarreal, S., Rameas, C. I., Collins, E. C., Towner, T. T., Varlinskaya, E. I., & Werner, D. F. (2024) · Alcohol · doi:10.1016/j.alcohol.2024.10.001 · Cited by 9
Vasopressin and oxytocin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
Bichet, D. G., Bouvier, M., Chini, B., Gimpl, G., Guillon, G., Kimura, T., Knepper, M. A., Lolait, S. J., Manning, M., Mouillac, B., et al. (2019) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f66/2019.4 · Cited by 9
High-Contrast PET Imaging of Vasopressin V1B Receptors with a Novel Radioligand, 11C-TASP699
Koga, K., Nagai, Y., Hanyu, M., Yoshinaga, M., Chaki, S., Ohtake, N., Ozaki, S., Zhang, M., Suhara, T., & Higuchi, M. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.188698 · Cited by 9
Török, B., Fodor, A., Zsebők, S., Sipos, E., & Zelena, D. (2021) · Brain Sciences · doi:10.3390/brainsci11040444 · Cited by 9
“antagonist of V1bRs (SSR149415) in adult rodent models had anxiolytic and antidepressantlike effects [25].”
BackgroundBakoev, S., Korobeinikova, A. V., Mishina, A. I., Kabieva, S. S., Игоревич, М. С., Ивашечкин, А. А., Akinshina, A. I., Snigir, E. A., Yudin, S. M., Yudin, V. S., et al. (2023) · Genes · doi:10.3390/genes14112053 · Cited by 8
“The importance of the AVPR1A gene in the control of social interaction, altruistic behavior, and pairing in humans has also been documented [36,52,53].”
BackgroundIdentification of novel selective V2 receptor non-peptide agonists
Tredici, A. L. D., Vanover, K. E., Knapp, A. E., Bertozzi, S. M., Nash, N. R., Burstein, E. S., Lameh, J., Currier, E. A., Davis, R. E., Brann, M. R., et al. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.08.004 · Cited by 8
Никитина, И. Л., Beeraka, N. M., Gaisina, G. G., Bulygin, K. V., Фанисовна, Г. Э., Galimov, S. N., Nikolenko, V. N., Михалева, Л. М., Somasundaram, S. G., Kirkland, C. E., et al. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210301115028 · Cited by 8
V1b Receptors: New Probes for Therapy
Arban, R. (2007) · Endocrinology · doi:10.1210/en.2007-0735 · Cited by 8
Letourneau, J. J., Riviello, C. M., Li, H., Cole, A. G., Ho, K.-K., Zanetakos, H. A., Desai, H., Zhao, J., Auld, D. S., Napier, S. E., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.07.118 · Cited by 8
Inatani, S., Mizuno‐Yasuhira, A., Kamiya, M., Nishino, I., Sabia, H. D., & Endo, H. (2021) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2273 · Cited by 7
“To date, several V1B receptor antagonists have been proven to exhibit antidepressant‐like effects in rodent models (Geneste et al., 2018; Griebel et al., 2002; Iijima et al., 2014).”
BackgroundNapier, S. E., Letourneau, J. J., Ansari, N., Auld, D. S., Baker, J. Α., Best, S. A., Campbell-Wan, L., Chan, J.-H., Craighead, M. W., Desai, H., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.081 · Cited by 7
Napier, S. E., Letourneau, J. J., Ansari, N., Auld, D. S., Baker, J. Α., Best, S. A., Campbell-Wan, L., Chan, R., Craighead, M. W., Desai, H., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.04.022 · Cited by 7
Inflammation and vasopressin hypersecretion in aging
Mutig, K., Lebedeva, S. A., & Singh, P. B. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1689787 · Cited by 6
Conivaptan for the treatment of hyponatremia
Zeltser, D., & Steinvil, A. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.16 · Cited by 6
Belyakova, A. S., Sinjushin, A. A., Voskresenskaya, O. G., Kamensky, A. A., & Golubovich, V. P. (2015) · Neurochemical Journal · doi:10.1134/s1819712415030034 · Cited by 6
Novel, potent, selective and brain penetrant vasopressin 1b receptor antagonists
Geneste, H., Bhowmik, S., van Gaalen, M. M., Hornberger, W., Hutchins, C. W., Netz, A., Oost, T. K., & Unger, L. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.07.043 · Cited by 6
Chekmareva, N. Y., Sotnikov, S., Diepold, R. P., Naik, R. R., Landgraf, R., & Czibere, L. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00087 · Cited by 6
“The anxiolytic effects of EE and the anxiogenic effects of CMS have been repeatedly shown in different studies (Griebel et al., 2002; Tannenbaum et al., 2002; Benaroya-Milshtein et al., 2004; Willner, 2005; Sztainberg et al., 2010).”
Type, Topography, and Sequelae of Neuropathological Changes Shaping Clinical Phenotype of Autism
Węgiel, J., Wısnıewskı, T., Chauhan, A., Chauhan, V. P. S., Kuchna, I., Nowicki, K., Imaki, H., Wegiel, J., Ma, S., Wierzba‐Bobrowicz, T., et al. (2009) · CRC Press eBooks · doi:10.1201/9781420068870-c1 · Cited by 6
Modulation von Peptidrezeptoren
Tracik, F. M., Lieb, K., Bauer, M., & Ströhle, A. (2005) · Springer eBooks · doi:10.1007/3-540-28049-9_38 · Cited by 6
Repetitive Transcranial Magnetic Stimulation Effects in vitro and in Animal Models
Keck, M. E. (2007) · KARGER eBooks · doi:10.1159/000101018 · Cited by 6
New Pharmacological Treatment Approaches for Anxiety Disorders
Ströhle, A. (2005) · Handbook of experimental pharmacology · doi:10.1007/3-540-28082-0_18 · Cited by 6
Petri, A., Sullivan, A., Allen, K., & Sachs, B. D. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1315366 · Cited by 5
Boominathan, M., Nagaraj, M., Muthusubramanian, S., & Bhuvanesh, N. S. P. (2014) · RSC Advances · doi:10.1039/c4ra02091j · Cited by 5
Амикишиева, А. В., Ilnitskaya, S. I., Nikolin, V. P., & Na, P. (2011) · PubMed · Cited by 5
Recent Strategies for the Development of New Antidepressant Drugs
Evrard, D. A. (2006) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(06)41002-2 · Cited by 5
Süyen, G. G., & Işbil-Büyükcoşkun, N. (2005) · Neuropeptides · doi:10.1016/j.npep.2005.09.002 · Cited by 5
Biological Alterations in Depression
Benton, C. S., & Wiltshire, T. (2011) · InTech eBooks · doi:10.5772/27658 · Cited by 5
Vasopressin: Roles in Modulating Social Behaviors
Williams, S. K., & Cymerblit‐Sabba, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803592-4.00057-2 · Cited by 5
Nonpeptide vasopressin V1b receptor antagonists
Griebel, G., & Gal, C. S. (2005) · Techniques in the behavioral and neural sciences · doi:10.1016/s0921-0709(05)80066-5 · Cited by 5
Self-citation„Stare” i „nowe” neuropeptydy jako modulatory czynności osi stresu (podwzgórze–przysadka–nadnercza)
Gołyszny, M. J. (2018) · Via Medica Journals · Cited by 4
Mutagenesis and Knockout Models: Hypothalamic-Pituitary-Adrenocortical System
Keck, M. E., & Müller, M. B. (2005) · Handbook of experimental pharmacology · doi:10.1007/3-540-28082-0_4 · Cited by 4
Russell, R. J., Doyle, R., Turner, J., Attkins, N., Ramsey, S. J., Weibley, L., Bateman, L., Bictash, M., Neal-Morgan, S., Ivarsson, M., et al. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.09.034 · Cited by 4
Klein, L. C., Corwin, E. J., & Ceballos, R. M. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511841262.011 · Cited by 3
Behavioral Testing Design for Evaluation of Cognitive Disabilities
Riet, F., Mittelhaeuser, C., Lux, A., Bour, R., Selloum, M., Sorg, T., Hérault, Y., & Méziane, H. (2022) · Current Protocols · doi:10.1002/cpz1.382 · Cited by 3
“The plus maze test is frequently used for evaluation of anxiolytic and anxiogenic effects of substances (Griebel et al., 2002), as well as for phenotypic evaluation of genetically modified mice (Danglot et al., 2012).”
BackgroundVerbalis, J. G. (2009) · Elsevier eBooks · doi:10.1016/b978-008088783-8.00049-8 · Cited by 3
Metadata
- Authors
- Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P.
- Affiliations
- Sanofi (France) (FR)
- Sanofi–Synthelabo Recherche, Avenue P. V.-Couturier, 92220 Bagneux, France; Sanofi–Synthelabo Recherche, Route d'Espagne, 31100 Toulouse, France; and Sanofi–Synthelabo Recherche, Rue du Professeur Blayac, 34000 Montpellier, France
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-04-16
- Volume
- 99
- Issue
- 9
- Pages
- 6370-6375
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC122955
- OpenAlex
- W2003547326
- Cited by
- 471
- References
- 31
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 6 · 2023: 6 · 2022: 8 · 2021: 12 · 2020: 14 · 2019: 10 · 2018: 15 · 2017: 8 · 2016: 20 · 2015: 18 · 2014: 29 · 2013: 16 · 2012: 21
- FWCI
- 10.11
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- non-peptide antagonists, anxiolytic effects, antidepressant effects, anxiety, depression, chronic mild stress, social defeat, traumatic stress, emotional processing, hypophysectomy, mood disorders
- MeSH terms
- Animals, Antidepressive Agents, Antidepressive Agents, Tricyclic, Anxiety, Behavior, Animal, Depression, Feeding Behavior, Fluoxetine, Imipramine, Indoles, Kinetics, Male, Mice, Inbred BALB C, Pyrrolidines, Stress, Physiological, Stress, Psychological, Time Factors, Anti-Anxiety Agents, Rats, Sprague-Dawley, Rats, Wistar, Risk Assessment, Antidepressive Agents, Second-Generation, Mice, Rats, Antidiuretic Hormone Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.